Navigation Links
Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer
Date:5/28/2009

ht loss, anorexia, nausea and hand-foot skin reaction. Grade 3/4 adverse events were 45% for Nexavar vs. 32% for placebo. Women of child-bearing potential should be advised to avoid becoming pregnant and advised against breast-feeding. In cases of any severe or persistent side effects, temporary treatment interruption, dose modification or permanent discontinuation should be considered.

For information about Nexavar including U.S. Nexavar prescribing information, visit www.nexavar.com or call 1.866.NEXAVAR (1.866.639.2827).

About Tarceva

Tarceva is a once-a-day pill that targets the EGFR pathway. Tarceva is designed to inhibit the tyrosine kinase activity of the EGFR signaling pathway inside the cell, one of the critical growth factors in NSCLC and pancreatic cancers. Tarceva is indicated as a monotherapy for patients with locally advanced or metastatic NSCLC whose disease has progressed after one or more courses of chemotherapy. Results from two multicenter, placebo-controlled, randomized Phase 3 trials conducted in first-line patients with locally advanced or metastatic NSCLC showed no clinical benefit with the concurrent administration of Tarceva with platinum-based chemotherapy (carboplatin and paclitaxel or gemcitabine and cisplatin) and its use is not recommended in that setting.

In pancreatic cancer, Tarceva is indicated in combination with gemcitabine for the first-line treatment of patients with locally advanced pancreatic cancer, pancreatic cancer that cannot be surgically removed or pancreatic cancer that has spread to distant body organs.

Important Safety Information For Tarceva

There have been infrequent reports of serious Interstitial Lung Disease (ILD)-like events including deaths in patients taking Tarceva. Serious side effects (including deaths) in patients taking Tarceva include liver and/
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc.; OSI Pharmaceuticals; Onyx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Ceregene Presents Additional Clinical Data from Phase 2 Trial of CERE-120 for Parkinsons Disease
2. The National Association of Boards of Pharmacy (NABP) Moves to Next Phase of Technician Recognition and Regulation
3. MAP Pharmaceuticals Phase 3 Trial of LEVADEX(TM) Migraine Product Candidate Meets All Four Primary Endpoints
4. Bioniche Phase III Clinical Trial with Urocidin(TM) Progressing Well
5. National Medical Interpreter Certification Testing Enters Pilot Phase
6. Results of phase III study on Labopharms novel antidepressant published in Psychiatry (Edgemont) Journal
7. Trubion Pharmaceuticals, Inc. to Present Positive Data From a Phase 2b Re-treatment Study of TRU-015 at the 2009 EULAR Annual Meeting
8. Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Sarcoma and Osteosarcoma: Phase I/II and Phase II Studies, ASCO 2009
9. InDex Pharmaceuticals AB Engages PharmaVentures to Facilitate the Licensing of Kappaproct(R) After Phase IIa Trial Achieves Clinical Endpoints Early
10. BioVex To Announce Updated Survival Data From a Phase II Clinical Study of OncoVEX GM-CSF in Metastatic Melanoma at The 2009 American Society of Clinical Oncology Meeting
11. Kinovate Life Sciences, Inc. and Nitto Denko Corporation Announce Successful Development of NittoPhase™ HL High Loading Solid Support for Oligonucleotide Synthesis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/21/2014)... AZ (PRWEB) December 21, 2014 Parker ... range of heating, cooling, plumbing and other similar home ... in 2014 with regard to its expert contracting services. ... industry leader that has been serving Arizona for well ... in providing the absolute best in quality customer service ...
(Date:12/21/2014)... CannabisClassifieds.com celebrates marijuana’s new legal place at the ... its kind, the site has provided its faithful users with ... running. It uniquely combines the benefits of platforms like ... to the masses. Assuring the potent herb’s followers it’s ... public approval. , Shane Chattin, Owner of Cannabis ...
(Date:12/20/2014)... MissyDress, a distinguished special dress supplier, has just ... has drastically cut prices to all its prom dresses ... 30, 2015. Many of the hottest styles are sold ... dresses, and more. , A spokesman for MissyDress says, ... A-line princess prom dresses or sweetheart chiffon prom dresses, ...
(Date:12/20/2014)... The print component of Healthy Aging ... of approximately 160,000 copies and an estimated readership of ... vast social media strategy and across a network of ... digital version of the campaign, click here . ... the ladies of CTV’s The Social. Lainey Lui, ...
(Date:12/20/2014)... 20, 2014 As Risperdal lawsuits ... in U.S. courts, Bernstein Liebhard LLP notes the ... children treated with the medication may experience elevated ... development and lactation. The study, which appears in ... adolescents who began treatment with risperidone, an antipsychotic ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Number Of Favorable Reviews In 2014 With Regard To Its Expert Contracting Services 2Health News:Parker & Sons Announces Record Number Of Favorable Reviews In 2014 With Regard To Its Expert Contracting Services 3Health News:CannabisClassifieds.com Maintains its “Craigslist for Cannabis” Standing with Website Re-launch 2Health News:MissyDress: The Prices of Prom Dresses Just Reduced 2Health News:The ladies of The Social urge Canadian women to put themselves first over the holiday season and into the new year in Mediaplanet’s “Women’s Health” campaign 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 3Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 4
... , Republican Congressman Slated to Oppose President Obama,s ... Insurance Campaign Contributions , , WASHINGTON, Sept. ... questions about Rep. Charles Boustany (R-La.) and the expected opposing remarks ... to a joint session of Congress on health care reform. , ...
... , , , WASHINGTON, ... the National Governors Association will speak at a National Press Club luncheon ... Rx for Health Reform: Affordable, Accessible, Accountable which looks ... health care reform. , , (Logo: ...
... prevent sudden cardiac death, researchers recommend electrocardiograms , WEDNESDAY, ... tested for heart abnormalities to prevent sudden cardiac death ... Sudden cardiac death is the leading cause of death ... it is, as figures vary and mandatory reporting does ...
... , ARMONK, N.Y., Sept. 9 Reducing the risk of ... among the top concerns of the pharmaceutical and life sciences industries today, ... IBM ) study. More than 50 percent of executives polled ... emergencies because of lapses in their supply chain. , , ...
... , , LEWISTON, Maine and THOUSAND ... sponsor of The Dempsey Challenge: A Journey for Hope, a cycling and ... supports The Patrick Dempsey Center for Cancer Hope & Healing at Central ... an opportunity to expand Amgen,s Breakaway from Cancer ((R)) ...
... , , FRANKLIN, Mass., Sept. 9 ... diabetes management company developing the needle-free Symphony(TM) tCGM System ... system and the Prelude(TM) SkinPrep System for transdermal drug ... presentation at the Rodman & Renshaw 2009 Annual Global ...
Cached Medicine News:Health News:Rep. Boustany Hauled in $1.25 Million From Health and Insurance Industry 2Health News:NGA Chair, Vermont Governor Douglas to Speak on States' Role in Health Care Reform at the National Press Club on September 17 2Health News:Testing Young Athletes for Heart Defects May Save Lives 2Health News:IBM Study Reveals Drug Companies Struggle to Improve Supply Chain to Battle Counterfeiting, Safety Concerns and Global Complexity 2Health News:IBM Study Reveals Drug Companies Struggle to Improve Supply Chain to Battle Counterfeiting, Safety Concerns and Global Complexity 3Health News:IBM Study Reveals Drug Companies Struggle to Improve Supply Chain to Battle Counterfeiting, Safety Concerns and Global Complexity 4Health News:Amgen Named Presenting Sponsor of The Dempsey Challenge: A Journey For Hope 2Health News:Amgen Named Presenting Sponsor of The Dempsey Challenge: A Journey For Hope 3Health News:Amgen Named Presenting Sponsor of The Dempsey Challenge: A Journey For Hope 4Health News:Echo Therapeutics Announces New Presentation Time at Rodman & Renshaw 2009 Annual Global Investment Conference 2
(Date:12/19/2014)... Ill. , Dec. 19, 2014   Hospira, ... leading provider of injectable drugs and infusion technologies, today ... Morgan 33rd Annual Healthcare Conference on Wednesday, Jan. 14, ... presentation is scheduled to begin at 10:30 a.m. Pacific ... available to all interested parties through a live audiocast ...
(Date:12/19/2014)... CARDIFF-BY-THE-SEA, Calif. , Dec. 19, ... SRNE ;  Sorrento), an oncology company developing new ... Inc., a privately-held immuno-oncology company developing proprietary Neukoplast ... based therapy, announced today that the companies have ... next generation CAR-TNK™ (pronounced as "Car-Tank") immunotherapies for ...
(Date:12/19/2014)... LOS ALTOS, Calif. , Dec. 18, 2014 ... of a new generation of equipment for the ... today the release of the new Luminary™ Profiler, ... highly accurate light-based measurement in a cost-effective, portable ... to meet the specific needs of the cannabis ...
Breaking Medicine Technology:Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5Sage Analytics Develops Breakthrough System for Potency Testing of Cannabis Products 2
... October 12, 2011 Leading health ... titles freely available through UN developing world research access ... scientific, technical and medical information products and services, today ... books to Research4Life , a public-private partnership working ...
... Mass., Oct. 11, 2011 Boston Scientific Corporation (NYSE: ... results for the third quarter ended September 30, 2011 on ... call will be hosted by Hank Kucheman, who becomes Boston ... Executive Vice President and Chief Financial Officer. A ...
Cached Medicine Technology:Elsevier Offers 950 New Health Titles to Research4Life 2Elsevier Offers 950 New Health Titles to Research4Life 3Boston Scientific To Webcast Conference Call Discussing Third Quarter 2011 Financial Results 2
... CMGS-1 Color Mini-Ganzfeld Stimulator is an advanced, ... integrated with your existing LKC system or ... visual electrodiagnostic test systems. Using LKCs ... smallest commercial Ganzfeld to meet ISCEV (International ...
... UTAS-E 3000 is the most advanced ... and accurate measurements of retinal and ... easy-to-use software available drives this powerful ... as adjustable contrast pattern stimulation, rapid ...
... CC cages are designed to facilitate an ... approach. These are interbody cages allowing radicular ... interve rtebral space and of the foramina, ... are particularly indicated for major lumbar instabilities.,CC ...
... SHELLGEL is a sterile nonpyrogenic, transparent ... SHELLGEL contains 12 mg/mL of high molecular ... hyaluronate dissolved in physiological saline. In the ... is 105,000 cps (105 Pa s) at ...
Medicine Products: